Glycan structure determinants for cation-independent mannose 6-phosphate receptor binding and cellular uptake of a recombinant protein.

The cation-independent mannose 6-phosphate receptor (CI-MPR) plays a critical role in intracellular transport of lysosomal enzymes as well as the uptake of recombinant proteins. To define the minimal glycan structure determinants necessary for receptor binding and cellular uptake, we synthesized a series of glycans containing mono-, di-, tri-, tetra-, and hexamannoses terminated with either one or two phosphates for conjugating to a model protein, recombinant human acid α-glucosidase. A high affinity interaction with the CI-MPR can be achieved for the enzyme conjugated to a dimannose glycan with a single phosphate. However, tightest binding to a CI-MPR affinity column was observed with a hexamannose structure containing two phosphates. Moreover, maximal cellular uptake and a 5-fold improvement in in vivo potency were achieved when the bisphosphorylated hexamannose glycan is conjugated to the protein by a β linker. Nevertheless, even a monophosphorylated dimannose glycan conjugate showed stronger binding to the receptor affinity column, higher cellular uptake, and significantly greater in vivo efficacy compared to the unconjugated protein which contains a low level of high affinity glycan structure. These results demonstrate that the phosphorylated dimannose moiety appears to be the minimal structure determinant for enhanced CI-MPR binding and that the orientation of the glycan is critical for maximum receptor interaction. In summary, we have improved the understanding of the mechanism of CI-MPR binding and developed a simple alternative for CI-MPR targeting.

[1]  J. Charrow,et al.  Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment , 2012, Journal of Inherited Metabolic Disease.

[2]  David F. Smith,et al.  The glycan-binding properties of the cation-independent mannose 6-phosphate receptor are evolutionary conserved in vertebrates. , 2012, Glycobiology.

[3]  K. McKeage,et al.  Mogamulizumab: first global approval. , 2012, Drugs.

[4]  R. J. Solá,et al.  Glycosylation of Therapeutic Proteins , 2010, BioDrugs.

[5]  P. Carter,et al.  Introduction to current and future protein therapeutics: a protein engineering perspective. , 2011, Experimental cell research.

[6]  S. M. Van Patten,et al.  Strategies for Neoglycan conjugation to human acid α-glucosidase. , 2011, Bioconjugate chemistry.

[7]  A. Pestronk,et al.  A randomized study of alglucosidase alfa in late-onset Pompe's disease. , 2010, The New England journal of medicine.

[8]  V. Tesar,et al.  Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact , 2010, European Journal of Clinical Pharmacology.

[9]  David F. Smith,et al.  Cation-independent Mannose 6-Phosphate Receptor , 2009, The Journal of Biological Chemistry.

[10]  David F. Smith,et al.  Glycan Microarray Analysis of P-type Lectins Reveals Distinct Phosphomannose Glycan Recognition* , 2009, The Journal of Biological Chemistry.

[11]  J. Clancy,et al.  Early Treatment With Alglucosidase Alfa Prolongs Long-Term Survival of Infants With Pompe Disease , 2009, Pediatric Research.

[12]  R. Mattaliano,et al.  Glycoengineered Acid α-Glucosidase With Improved Efficacy at Correcting the Metabolic Aberrations and Motor Function Deficits in a Mouse Model of Pompe Disease. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  B. Byrne,et al.  Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease , 2009, Genetics in Medicine.

[14]  Jung‐Ja P. Kim,et al.  Strategies for carbohydrate recognition by the mannose 6-phosphate receptors. , 2008, Glycobiology.

[15]  M. O'Callaghan,et al.  Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease. , 2008, Molecular genetics and metabolism.

[16]  M. Hulett,et al.  Cell Surface-expressed Cation-independent Mannose 6-Phosphate Receptor (CD222) Binds Enzymatically Active Heparanase Independently of Mannose 6-Phosphate to Promote Extracellular Matrix Degradation* , 2008, Journal of Biological Chemistry.

[17]  M. Gary‐Bobo,et al.  Mannose 6-phosphate receptor targeting and its applications in human diseases. , 2007, Current medicinal chemistry.

[18]  S. M. Van Patten,et al.  Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease. , 2007, Glycobiology.

[19]  W. Sly,et al.  Enzyme therapy in mannose receptor-null mucopolysaccharidosis VII mice defines roles for the mannose 6-phosphate and mannose receptors , 2006, Proceedings of the National Academy of Sciences.

[20]  N. Raben,et al.  Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice. , 2005, The Biochemical journal.

[21]  R. Moreland,et al.  Lysosomal Acid α-Glucosidase Consists of Four Different Peptides Processed from a Single Chain Precursor* , 2005, Journal of Biological Chemistry.

[22]  D. Berkowitz,et al.  Mono- and bivalent ligands bearing mannose 6-phosphate (M6P) surrogates: targeting the M6P/insulin-like growth factor II receptor. , 2004, Organic letters.

[23]  Qun Zhou,et al.  Conjugation of Mannose 6-Phosphate-containing Oligosaccharides to Acid α-Glucosidase Improves the Clearance of Glycogen in Pompe Mice* , 2004, Journal of Biological Chemistry.

[24]  Sreelatha T. Reddy,et al.  Identification of a Low Affinity Mannose 6-Phosphate-binding Site in Domain 5 of the Cation-independent Mannose 6-Phosphate Receptor* , 2004, Journal of Biological Chemistry.

[25]  Jung‐Ja P. Kim,et al.  The N-terminal Carbohydrate Recognition Site of the Cation-independent Mannose 6-Phosphate Receptor* , 2004, Journal of Biological Chemistry.

[26]  S. Kornfeld,et al.  Mannose 6-phosphate receptors: new twists in the tale , 2003, Nature Reviews Molecular Cell Biology.

[27]  M. Hancock,et al.  Localization of the Carbohydrate Recognition Sites of the Insulin-like Growth Factor II/Mannose 6-Phosphate Receptor to Domains 3 and 9 of the Extracytoplasmic Region* , 2002, The Journal of Biological Chemistry.

[28]  M. Hancock,et al.  Identification of Residues Essential for Carbohydrate Recognition by the Insulin-like Growth Factor II/Mannose 6-Phosphate Receptor* , 2002, The Journal of Biological Chemistry.

[29]  K. von Figura,et al.  Function and Properties of Chimeric MPR 46-MPR 300 Mannose 6-Phosphate Receptors* , 2000, The Journal of Biological Chemistry.

[30]  S. Kornfeld,et al.  The Rate of Internalization of the Mannose 6-Phosphate/Insulin-like Growth Factor II Receptor Is Enhanced by Multivalent Ligand Binding* , 1999, The Journal of Biological Chemistry.

[31]  N. Raben,et al.  Targeted Disruption of the Acid α-Glucosidase Gene in Mice Causes an Illness with Critical Features of Both Infantile and Adult Human Glycogen Storage Disease Type II* , 1998, The Journal of Biological Chemistry.

[32]  D. Sleat,et al.  Ligand Binding Specificities of the Two Mannose 6-Phosphate Receptors* , 1997, The Journal of Biological Chemistry.

[33]  M. Meldal,et al.  Constrained glycopeptide ligands for MPRs. Limitations of unprotected phosphorylated building blocks. , 1997, Bioorganic & medicinal chemistry.

[34]  B. Hoflack,et al.  Cloning and sequencing of cDNAs encoding the full-length mouse mannose 6-phosphate/insulin-like growth factor II receptor. , 1994, Gene.

[35]  P. Rotwein,et al.  The mouse insulin-like growth factor II/cation-independent mannose 6-phosphate (IGF-II/MPR) receptor gene: molecular cloning and genomic organization. , 1994, Genomics.

[36]  W. Kiess,et al.  Expression of the insulin-like growth factor-II/mannose-6-phosphate receptor in multiple human tissues during fetal life and early infancy. , 1992, The Journal of clinical endocrinology and metabolism.

[37]  O. Hindsgaul,et al.  The binding specificity of high and low molecular weight phosphomannosyl receptors from bovine testes. Inhibition studies with chemically synthesized 6-O-phosphorylated oligomannosides. , 1991, The Journal of biological chemistry.

[38]  H. Tomoda,et al.  Binding specificity of D-mannose 6-phosphate receptor of rabbit alveolar macrophages. , 1991, Carbohydrate research.

[39]  S. Kornfeld,et al.  Ligand interactions of the cation-independent mannose 6-phosphate receptor. The stoichiometry of mannose 6-phosphate binding. , 1989, The Journal of biological chemistry.

[40]  W. Sly,et al.  The human cation-independent mannose 6-phosphate receptor. Cloning and sequence of the full-length cDNA and expression of functional receptor in COS cells. , 1988, The Journal of biological chemistry.

[41]  S. Kornfeld,et al.  Cloning and sequence analysis of the cation-independent mannose 6-phosphate receptor. , 1988, The Journal of biological chemistry.

[42]  S. Kornfeld Trafficking of lysosomal enzymes 1 , 1987, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[43]  W. Rutter,et al.  Insulin-like growth factor II receptor as a multifunctional binding protein , 1987, Nature.

[44]  K. von Figura,et al.  Lysosomal enzymes and their receptors. , 1986, Annual review of biochemistry.

[45]  A. Varki,et al.  The spectrum of anionic oligosaccharides released by endo-beta-N-acetylglucosaminidase H from glycoproteins. Structural studies and interactions with the phosphomannosyl receptor. , 1983, The Journal of biological chemistry.